Radiopharm Theranostics Limited American Depositary Shares (RADX) - Total Liabilities
Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) has total liabilities worth $40.45 Million USD as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Radiopharm Theranostics Limited American Depositary Shares - Total Liabilities Trend (2022–2025)
This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's total liabilities have evolved over time, based on quarterly financial data. See RADX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Radiopharm Theranostics Limited American Depositary Shares Competitors by Total Liabilities
The table below lists competitors of Radiopharm Theranostics Limited American Depositary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Big Camera Corporation Public Company Limited
BK:BIG
|
Thailand | ฿1.09 Billion |
|
Accentis
BR:ACCB
|
Belgium | €18.28 Million |
|
Aberdeen Global IF Inc
NYSE MKT:FCO
|
USA | $17.48 Million |
|
Big Digital Energy, Inc.
NASDAQ:BGDE
|
USA | $60.56 Million |
|
Drone Volt SA
PA:ALDRV
|
France | €8.88 Million |
|
Zepp Health Corp
NYSE:ZEPP
|
USA | $2.56 Billion |
|
NUREXONE BIOLOGIC INC.
F:J90
|
Germany | €1.32 Million |
|
Vardhman Polytex Limited
NSE:VARDMNPOLY
|
India | Rs5.07 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Radiopharm Theranostics Limited American Depositary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Radiopharm Theranostics Limited American market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Radiopharm Theranostics Limited American Depositary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Radiopharm Theranostics Limited American Depositary Shares (2022–2025)
The table below shows the annual total liabilities of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $43.61 Million | -2.40% |
| 2024-06-30 | $44.68 Million | +52.14% |
| 2023-06-30 | $29.37 Million | +43.84% |
| 2022-06-30 | $20.42 Million | -- |
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more